Skip to content
Menu
Home
about AesMed
AesMed Story
AGF39
AesMed Successfully Concludes KIMES 2026 Participation
2026-04-07
AesMed is pleased to announce the successful completion of its participation in KIMES ...
Read More
Latest Posts
From Diagnosis to Clinical Protocol: CytoMesopecia by AesMed (Part 3)
How AGF39™ Supports the Hair Follicle Environment (Part 2)
What Is Korean Cytokines Mesotherapy for Hair Regrowth? (Part 1)
AesMed Selected as a “Global Leading Company 1,000+”
Beyond Korea, To the World: AesMed at WCHR 2026
AesMed to Exhibit at WCHR 2026 in Seoul and Introduce the 1111 Hair Care Day Campaign
AesMed Showcases Hair-Loss Treatment Innovations at KALDAT 2026 and KSHRS 2026
Beyond the Device: How SCALPORIN™ R1 Fits into AGF39 Protocols and the CytoMesopecia Concept
Inside SCALPORIN™ R1: AesMed’s Professional Electroporation Scalp Device for Precision Delivery
Why Delivery Matters in Scalp Care: Electroporation, Active Solutions, and the Logic Behind Professional Treatment
Search for:
